ABSTRACT Objective: To compare the angiogenesis behaviors of vascular endothelial growth factor (VEGF) and Chinese medicine Xuefu Zhuyu Decoction (血府逐瘀汤, XZD) treatments. Methods: Human microvascular endothelial cells (HMEC-1) were treated with various concentrations of either XZD-containing serum (XZD-CS) or VEGF for 24, 48, and 72 h, respectively. Cell viability, proliferation, migration, adhesion, and in vitro tube formation assays were used to assess their angiogenic effects. Results: VEGF promoted all cellular phases involved in angiogenesis including cell viability, proliferation, migration, adhesion, and tube formation (P<0.05 or P<0.01). Unlike the continuous promotion effects of VEGF at the above stages, XZD inhibited cell viability and proliferation (P<0.05 or P<0.01) and only promoted tube formation in the early phase of angiogenesis (P<0.01). Conclusions: These two medications promote different angiogenesis behaviors, which might be an important reason for their distinct therapeutic profile in clinical usage.
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and the most widely used pro-angiogenesis factor used in ischemic research. As the first drug in clinical trial for ischemic cardiovascular disease, VEGF may also hasten plaque angiogenesis to expand plaques, which makes it unstable and causes it to accelerate atherosclerosis. This angiogenesis activity at sites other than the target organ causes a Janus phenomenon, (1) in which excessive angiogenesis may also increase the potential risk of angiogenesis-borne diseases such as retinopathy and cancer. (2) (3) (4) The herbal formula Xuefu Zhuyu Decoction (血府 逐瘀汤, XZD), put in Chinese characters means driving out stasis from the mansion of blood, which was firstly recorded in 1830 AD in Corrections of Errors Among Physicians (Yi Lin Gai Cuo), is a classical herbal formula that activates blood circulation and removes blood stasis. XZD is commonly used to treat ischemic cardiovascular disease. It is often prepared as a capsule to improve palatability and increase its dosing convenience. Our preliminary works showed that XZD has a pro-angiogenesis effect on the chicken embryo chorioallantoic membrane; (5) additionally, its use can accelerate endothelial progenitor cells (Epcs) to form blood vessel in vitro, (6) mobilize Epcs to the ischemic region to repair injury, (7) and induce endothelial cell (ECV304) migration, adhesion, proliferation, and tube formation. (8) Clinical research has shown that XZD has effective anti-atherosclerosis properties and prevents vascular restenosis after percutaneous transluminal coronary angioplasty. (9, 10) Unlike VEGF, XZD has not been implicated in any Janus phenomenon, suggesting that it may control angiogenesis without carrying such risks. In this study, we investigated the differences in the underlying mechanisms of XZD and VEGF in the treatment of cardiovascular ischemia. 
METHODS

Preparation of XZD-Containing Serum
XZD Capsules were manufactured by Hongrentang Pharmaceutical Co., Ltd. (batch No. A03039, Tianjin, China). Six healthy male volunteers were chosen and the study was approved by the Human Experimentation Committee of Fujian University of Traditional Chinese Medicine. Firstly 50 mL of venous blood were drew from each participant as the control serum. Then the participants were given 5-fold the standard dose of XZD Capsules (equivalent to 2-fold crude dried herbs) per day. After 7 consecutive days, the venous blood were drew again 2 h after the capsules were ingested. Blood was centrifuged at 4,000 r/min for 30 min and the XZD-containing serum (XZD-CS) was collected. The XZD-CS and control serum were heat-inactivated at 56 ℃ for 30 min, sterile filtered through a 0.22-μm filter, and kept at -20 ℃ until use.
Cell Culture
The HMEC-1 cell line was provided by Prof. DING Jian of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Cells were cultured in MCDB-131 (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA), 10 ng/mL epidermal growth factor (Gibco), and 1 μg/mL hydrocortisone. Cells in the logarithmic growth phase were selected and seeded in culture plates or culture flasks. After adhering, they were starved in serum-free MCDB-131 for 12 h and then randomly divided into VEGF and XZD groups.
VEGF groups were stimulated with VEGF (Sigma-Aldrich; final concentrations of 1.25, 2.5, 5, and 10 ng/mL); XZD groups were stimulated with XZD-CS (final concentrations of 1.25%, 2.5%, and 5%). All groups were incubated in MCDB-131 supplemented with 5% fetal bovine serum (FBS) and treated with the corresponding medicine or controls for 24, 48, and 72 h.
Cell Viability Assay
A total of 3×10 3 cells/well were seeded into 96-well plates. After treatment with the corresponding medication or controls, 20 μL of methyl thiazolyl tetrazolium solution (5 mg/mL) was added to each well. Following incubation for 4 h, the supernatant was removed and the prepared HMEC-1 cells were shaken with 150 μL of dimethyl sulfoxide for 10 min before the optical density was assessed at 570 nm (reference wave, 630 nm) using a 96-well microplate reader (BioTek Instruments, Winooski, VT, USA).
Flow Cytometry
Cells cycle was tested by a fluorescence activated cell sorter as described in the instruction book of Cycle TEST™ plus DNA Reagent kit (Becton Dickinson, Franklin Lakes, NJ, USA). Cell Quest software (Becton Dickinson) was used to acquire the data and a ModiFit Version 3.0 (Becton Dickinson) was used for the analysis.
Cell Migration Assay
Cell migration was tested in Boyden Chambers (Jiangsu Qilin Medical Instrument Factory, China) with a polycarbonated filter (8-μm pore size, Whatman, Little Chalfont, UK). A total of 5×10 4 cells were plated into the upper chamber containing 100 μL of medium supplemented with 5% FBS. The lower chamber was filled with 150 μL of the corresponding cell culture supernatant. The cells were allowed to migrate for 8 h.
Following incubation at 37 ℃, the cells on the upper side of the membrane were removed, the membrane was fixed with 4% neutral formalin for 20 min, and the cells were stained with hematoxylin. Photographs were taken at a magnification of 200× by an inverted phase contrast microscope (IX70, Olympus, Tokyo, Japan). The stained cells were counted in 6 randomly selected fields.
Cell Adhesion Assay
Cells were seeded in a 96-well plate coated with 1% gelatin (Sigma-Aldrich) and incubated for 60 min. Then the medium containing non-adhered cells were discarded and the adhered cells were fixed with 4% neutral formalin for 20 min and stained them with 0.1% crystal violet. The stained cells were counted in 6 random fields (200×).
Endothelial Cell Tube Formation Assay
An ice-cold 96-well plate was coated with 50 μL/well Matrigel (Millipore Co., Billerica, MA, USA), which was allowed to solidify at 37 ℃ for 60 min according to the manufacturer instructions. HMEC-1 cells were seeded at a concentration of 1.8×10 5 cells in 150 μL/well culture medium supplemented with 5% FBS in triplicate. After 4-h incubation at 37 ℃ and 5% CO 2 , images were taken from each well at 200× magnification using an inverted phase contrast microscope (IX70, Olympus). The number of tubes in 6 randomly selected fields was counted.
Statistical Analysis
Data were expressed as mean ± standard deviation (x -±s) from three separate experiments. To avoid the effect of different sera, the XZD-CS-treated groups were compared with the same serum content control group using t-tests. VEGF-treated groups were compared with the control group using one-way analysis of variance, where significance was determined using the least significant differences test. P value less than 0.05 were considered statistically significant.
RESULTS
Effects of the Two Medicines on Cell Viability
VEGF 1.25 ng/mL enhanced cell activity ( Figure 1A ), but the effect was neither time-nor dosedependent. Compared with the equivalent serum content control group, the 1.25% and 2.5% XZD-CS concentrations inhibited cellular activity during the first 24 h and the 5% XZD-CS concentration promoted cellular activity at 48 h; however, all effects disappeared at 72 h ( Figures 1B-1D) , suggesting that the promotion function of VEGF was earlier and longer than that of the XZD Capsules on HMEC-1 activity.
Effects of the Two Medications on Cell Cycle
The VEGF 1.25 ng/mL concentration had a timedependent effect on increasing the ratio of the cellular S phase (Figure 2A) . Compared with the equivalent serum content control group, the 2.5% and 5% XZD-CS showed an inhibitory effect only at 72 h ( Figures 2B-2D ). The two medications had opposite effects on cell proliferation.
Effects of the Two Medications on Cell Migration
Considering that VEGF is a chemotactic factor but XZD is not, the cell culture supernatant was placed in the lower chamber to show the effect of medications working on the chemotactic factors. VEGF induced cell migration in a time-dependent manner ( Figure  3A) , no obvious effect of VEGF was seen in the first 24 h, but improved cell migration became evident at 48 h and even stronger at 72 h. Compared with the same serum content control group, all XZD-CS groups increased the degree of cell migration as early as 24 h ( Figures 3B-3D ), which suggested a quicker onset of this cellular behavior than that of VEGF and this nontime-dependent effect lasted to 72 h.
Effects of the Two Medications on Cell Adhesion
The VEGF 1.25-10 ng/mL groups increased the numbers of cells that adhered to the gelatincoated surfaces at the three time points ( Figure 4A) . Compared with the equivalent serum content control group, all XZD-CS induced cell adhesion at all three time points in a manner similar to that of VEGF ( Figures 4B-4D) . 
Effects of the Two Medications on Tube Formation
The VEGF groups promoted HMEC-1 tube formation at all the three time points ( Figure 5 ). While compared with the equivalent serum control, 1.25% XZD-CS improved tube formation at 24 and 48 h ( Figures 6B, 6D , and 6G), while 2.5% XZD-CS worked only at 24 h and its pro-angiogenesis effect disappeared at 48 h ( Figure 6H ). These results suggest that a low concentration of XZD promoted tube formation only during the early phase. This effect of XZD did not have persistence and sensitivity as effects of VEGF.
DISCUSSION
As a functional factor in vivo, VEGF can be added directly to cell culture medium. Because XZD Capsules consists of 11 Chinese herbs and its active pharmacological ingredients in the serum remain unknown, the serum pharmacological method was Angiogenesis is a complicated process involved with vascular endothelial cell migration, proliferation, adhesion, and formation of new blood vessels. In this study, except for cell adhesion, the two tested medicines worked in a different manner in each of the phases. VEGF promoted angiogenesis at all stages. In contrast, XZD inhibited cell vigor or proliferation at certain concentrations and induced tube formation to a limited degree at low concentrations and only over a short time frame. This short early pro-angiogenesis phenomenon of XZD also occurred in vivo in an earlier pilot study of repairing rat ischemic hind limb impairments. (7) XZD could only elevate the number of vessels in the granulation tissue at the early repair phase, whereas the number of vessels did not change in the ischemic muscle and the new vessel would occlude the granulation tissue fibrosis. These results suggest that XZD may control angiogenesis in a different manner from the continuous function of VEGF.
XZD is not the only Chinese medicine that can control vessel growth. Shexiang Baoxin Pills (麝香保心丸), a medication for coronary heart disease, appeared to promote angiogenesis in a rat myocardial infarction model (11) but inhibit vessel growth in cancer. (12) These two findings suggest that controlling vessel growth may be a characteristic of Chinese medicine. This might also explain the low rate of adverse events with Chinese medicine compared with the side effect of VEGF in clinical usage.
In some ways, XZD action on angiogenesis resembles VEGF. Early work by our group showed that XZD could induce angiogenesis in endothelial progenitor cells (13) and endothelial cell ECV304 via the VEGF pathway (8) and elevate serum VEGF levels in rats. (14) XZD can also affect other angiogenesis regulators such as nitric oxide and basic fibroblast growth factor. (8, 15) This multi-targeted action of XZD may be responsible for the differences in angiogenesis behavior between XZD and VEGF. The mechanisms of action of XZD require further in-depth research. Undoubtedly, the effective ingredients of XZD in serum are worthy of future research attention.
